# Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents

Source: https://onco.cc/trials/nct06120491/  
OnCo record `nct06120491` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

This study tests a PARP inhibitor; the registry reports that it is active not recruiting.

## Summary

The registry lists NCT06120491 as active not recruiting, last updated 2026-07-29. Enrolment is 1898 actual participants. Interventions: Saruparib, Placebo, Abiraterone Acetate, Darolutamide, Enzalutamide. Primary measures include Radiographic Progression-Free Survival (rPFS). No results are posted in the registry; this does not exclude separate publications.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-10-06
- Also known as: EvoPAR-Prostate01
- Tags: ctgov-ingest
- Registry id: NCT06120491
- Phase: 3
- Setting: A Randomized, 2-cohort, Double-blind, Placebo-controlled, Phase III Study of Saruparib (AZD5305) in Combination With Physician's Choice New Hormonal Agents in Patients With HRRm and Non-HRRm Metastatic Castration-Sensitive Prostate Cancer (EvoPAR-Prostate01)
- Sponsor: AstraZeneca
- Enrolled: 1898

## Sources

- ClinicalTrials.gov NCT06120491: https://clinicaltrials.gov/study/NCT06120491

## Connected records

- cancers: [Metastatic hormone-sensitive prostate cancer](https://onco.cc/cancers/prostate-mhspc/), [Prostate cancer](https://onco.cc/cancers/prostate/)
- targets: [PARP](https://onco.cc/targets/parp/)
- drugs: [Saruparib](https://onco.cc/drugs/saruparib/)
- companies: [AstraZeneca](https://onco.cc/companies/astrazeneca/)

---
JSON: https://onco.cc/api/v1/entities/nct06120491.json